ESMO 2025 breast cancer abstracts bring key updates. For example, Dr. Paolo Tarantino from Dana-Farber chose this top 10 list…
Introduction to a Revolutionary Cancer Approach This treatment starts with T cells from the patient. Doctors add receptors to spot…
Introduction to ESMO 2025 Genitourinary Cancer Abstracts ESMO 2025 genitourinary cancer abstracts show exciting new finds. For instance, they include…
Immune checkpoint inhibitors myocarditis poses a serious threat in cancer care. These drugs fight tumors well. However, they can inflame…
TIL Therapy Breakthroughs for Oncologists and Oncology Professionals Tumor-Infiltrating Lymphocyte (TIL) therapy is transforming melanoma care and continues to provide…
Introduction to Neoadjuvant Therapy for Melanoma Neoadjuvant therapy is changing how we treat melanoma, offering big benefits over traditional adjuvant…
The ESMO 2025 Congress, held October 17-21 in Berlin, will feature exciting breast cancer trials that could improve patient care.…
On September 6, 2025, at the MOASC and ANCO Immuno-Oncology Symposium, Dr. Alexis LeVee, MD, from UCLA’s Division of Hematology/Oncology,…
FDA Backs Lurbinectedin + Atezolizumab for ES-SCLC Care FDA approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals) with atezolizumab (Tecentriq, Genentech) or atezolizumab…
Introduction to ASCO 2025 Lung Cancer Immunotherapy Updates At the MOASC/ANCO Immuno-Oncology Symposium held on September 6, 2025, in Marina…
Introduction: A New Tool for Breast Cancer Treatment On September 25, 2025, the FDA approved Inluriyo (imlunestrant), an oral selective…
Uncommon EGFR Mutations Research Overview At MOASC Spotlight 2025, Dr. Darren Wijaya, MD, from Loma Linda University Health, shared vital…
In 2025, the US Surgeon General issued a pivotal advisory on alcohol and cancer risk, urging updated warning labels, patient…
Oncology changes quickly. The melanoma treatment updates 2025 from the ASCO Annual Meeting offer vital help. Dr. Gino K. In,…
Paraneoplastic syndromes can signal hidden cancers. Dr. Nirja Shah, MD, from UC San Diego Health, shared a rare case study.…
At the MOASC Spotlight 2025 in Newport, California, Dr. Victoria M. Villaflor, MD, shared exciting head and neck cancer ASCO…
Gastric cancer immunotherapy is advancing rapidly, bringing hope for better patient outcomes. Therefore, OncologyTube is excited to share insights from…
The ASCO 2025 breast cancer updates revealed exciting changes in treatment for triple-negative breast cancer (TNBC) and HER2-low cases. For…
At the 2025 MOASC Spotlight in Newport Beach, CA, Dr. Miguel Villalona-Calero, MD, from the University of California Irvine, shared…
At the MOASC Spotlight 2025, Dr. Joshua G. Cohen, M.D., F.A.C.O.G., F.A.C.S., Medical Director of the Gynecologic Cancer Program at City…
The FDA approved INLEXZO™ / gemcitabine intravesical on September 9, 2025, to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with…
ASCO 2025 and the MOASC Conference unveiled major progress in colon cancer treatment advancements. For example, the CHALLENGE study showed…
Genitourinary oncology is advancing fast. At the MOASC Spotlight on Oncology event on August 16, 2025, at VEA Newport Beach,…
This report examines the NSCLC HER3-DXd breakthrough. It focuses on its potential impact on patients with resistant EGFR-mutated non-small cell…
OncologyTube brings you an exclusive look at the AMPLIFY-201 Phase 1 trial. Furthermore, this study highlights ELI-002 2P, a lymph…
Explore our web companion for the video featuring insights from Roshni Rao, MD FACS, Chief of Breast Surgery at Columbia University.…
At the ASBrS 2025 annual meeting, Dr. Lucy Maria De La Cruz, MD, from Georgetown University Hospital, shared vital insights…
I’m sharing an actual recent peer-to-peer call that shows what physicians and patients face when trying to get a surgery…
What Are CDK4/6 Inhibitors? CDK4/6 inhibitors, such as abemaciclib and ribociclib, are changing breast cancer treatment for HR+/HER2- early-stage patients.…
Sensation-preserving mastectomies are transforming breast cancer surgery. They prioritize oncologic safety and sensory recovery. In an exclusive interview, Dr. Anne…
A major study, NRG-NSABP B-51/RTOG 1304, published on June 4, 2025, in the New England Journal of Medicine, shows regional…
The I-SPY2 Trial is transforming breast cancer treatment, offering new insights into pre-surgery chemotherapy for invasive lobular breast cancer (ILC).…
The 2025 Cell article by Catherine M. Phelps et al. from the University of Pittsburgh reveals a key connection between…
The U.S. healthcare sector is transforming rapidly, solidifying its position as the nation’s top expenditure and a powerhouse for job…
Breast surgery is transforming patient care with innovative approaches. Oncoplastic breast surgery, for instance, merges art and science to improve…
At ASBrS 2025, experts showcased how MRD testing in breast cancer is revolutionizing patient care. Using Natera’s Signatera, clinicians detect circulating tumor…
The Camizestrant SERENA-6 trial shone at ASCO 2025, presented by Professor Nick Turner. This Phase 3 study targets ESR1-mutated, ER-positive,…
Introduction to CT Scans and Cancer Computed Tomography (CT) scans are vital for diagnosing cancer, injuries, and chronic diseases. However,…
Introduction to Datopotamab Deruxtecan EGFR-Mutated NSCLC On June 23, 2025, the FDA approved Datopotamab Deruxtecan EGFR-Mutated NSCLC treatment, known as…
Introduction to Post-CDK4/6 Inhibitor Treatment Treating hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC) has improved with CDK4/6 inhibitors like…
The Matterhorn Trial, a landmark phase III study published in the New England Journal of Medicine, evaluates durvalumab, an anti-PD-L1…
FDA Voucher Program Oncology: Accelerated Approvals in Oncology On June 17, 2025, the FDA launched the Commissioner’s National Priority Voucher…
Welcome to this comprehensive web companion for the OncologyTube.com video, “HR+/HER2- metastatic breast cancer 2L outcomes: Top 10 from ASCO…
Welcome to this exclusive OncologyTube.com companion to our video, “Comprehensive Overview of Bispecific Antibodies in Cancer Therapy.” Bispecific antibodies (bsAbs)…
China is making significant strides in oncology research. Data from the IQVIA Global Oncology Trends 2025 report highlights China’s growing…
Introduction to HCC Treatment Insights Hepatocellular carcinoma (HCC) presents tough treatment challenges, requiring careful patient selection for local therapies. This…
On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a new kinase…
The ASCO 2025 conference, held recently, shared new research that may shape cancer treatments. This article covers studies on treatment-induced…
Digestive cancers therapeutics takes center stage as these cancers—esophageal, gastric, biliary, pancreatic, hepatocellular, and colorectal—account for 33-35% of global cancer…
On June 3, 2025, the U.S. Food and Drug Administration (FDA) approved Darolutamide for de novo metastatic castration-sensitive prostate cancer…
Tarlatamab Phase 3 Results SCLC ASCO 2025 The tarlatamab phase 3 results for SCLC, shared at ASCO 2025, showed a…
Introduction to Pancreatic Cancer Treatment at ASCO 2025 At the ASCO 2025 Annual Meeting, Dr. Brian Wolpin presented groundbreaking updates…
At the 2025 ASCO Annual Meeting, new data on IO-based combinations in mRCC emerged. For instance, Dr. Brian Rini, MD…
Published: June 4, 2025Category: Lung Cancer Research Introduction to Neoadjuvant Nivolumab Plus Chemotherapy in CheckMate 816 The CheckMate 816 trial…
This video presents the myeloma treatment algorithm 2025 for transplant-ineligible patients, shared by Dr. Vincent Rajkumar at ASCO 2025. Designed…
At the 2025 ASCO Annual Meeting, a phase 3 randomized trial revealed that the timing of immunotherapy in non-small cell…
What’s New at ASCO 2025? The ASCO 2025 conference in Chicago brought exciting news for cancer care. A major study,…
ATOMIC Trial ASCO 2025: Key Results RevealedOn June 1, 2025, the ASCO Annual Meeting in Chicago presented the ATOMIC trial…
Introduction Cancer of Unknown Primary (CUP) diagnostics is a critical area for oncologists and researchers, as 2-5% of cancer cases…
Published: May 30, 2025 Pfizer shared results from the BRAFTOVI BREAKWATER trial at ASCO 2025. The trial tested BRAFTOVI® (encorafenib) with cetuximab…
Posted on May 30, 2025 by ASCO Editorial Team Artificial intelligence (AI) is reshaping the future of cancer research and…
The Top 10 GI Trials at ASCO 2025 are here (with Dates and Times), and OncologyTube proudly presents an exclusive…
Former President Joe Biden’s Stage 4 prostate cancer diagnosis, announced on May 27, 2025, raises profound questions. When did this…
OncologyTube.com presents the ASCO 2025 Top 10 Abstracts, highlighting practice-changing trials in oncology. It features advancements in cancer care, from…
Publish Date: May 23, 2025Category: Cancer Research Funding Introduction to the 2026 Cancer Research Budget The proposed 2026 cancer research…
The American Society of Clinical Oncology (ASCO) Annual Meeting is a pivotal event for oncology professionals, and ASCO 2025, happening…
RAS Inhibitor Resistance in PDAC at AACR 2025 At the AACR 2025 Annual Meeting in Chicago, Dr. Andrew Aguirre from…
A New Approach to MMRd/MSI-H Tumors At the AACR Annual Meeting 2025 in Chicago, Dr. Andrea Cercek presented compelling data…
Published on May 3, 2025 Antibody-drug conjugates (ADCs) have revolutionized oncology, offering targeted cancer treatments that minimize harm to healthy…
Introduction Zongertinib (BI 1810631) has shown promising results in treating HER2-mutant non-small cell lung cancer (NSCLC), with a 71% response…
Introduction The KEYNOTE-689 clinical trial has provided a significant update on pembrolizumab’s role in treating resectable locally advanced head and…
FDA approves Penpulimab-kcqx / Anike The FDA approved Anike (Penpulimab-kcqx) on April 23, 2025, for non-keratinizing nasopharyngeal carcinoma (NPC, WHO…
Published: April 21, 2025 | OncologyTube.com A groundbreaking phase III study, published on April 11, 2025, in the Journal of…
The 2025 ASCO guidelines on sentinel lymph node biopsy (SLNB) for early-stage breast cancer are reshaping oncology care. Published in the Journal of Clinical Oncology, these recommendations, backed by extensive clinical trials, aim to reduce unnecessary procedures, lower costs, and address health disparities. Learn about the six key updates, their impact on patients, and how they promote personalized treatment while minimizing complications like lymphedema. Visit OncologyTube.com for more insights.
Date: April 8, 2025 On April 8, 2025, the FDA granted regular approval to nivolumab (Opdivo) combined with ipilimumab (Yervoy)…
April 06, 2025 | By Nataliya Mar, MD, Associate Professor, UC Irvine The American Society of Clinical Oncology Genitourinary Cancers…
By Samuel Zeng, MD – UCLAPosted on April 4, 2025 When chest pain strikes a patient with a history of…
By: Neil Chawla, MD – Oncologist and Researcher at the Cancer Center of SouthernCalifornia and Sarcoma Oncology Center Introduction to…
By: Hamid Mirshahidi, MD – Loma Linda University The AACR 9th Edition has introduced significant changes to the TNM staging…
By Dr. Bradley McGregor | Published April 02, 2025 Renal cell cancer (RCC) treatment continues to evolve, and Tivozanib (TIVO)…
In the 2025 MOASC Breast Cancer Updates, Evanthia Roussos Torres, MD, delivers a compelling overview of the current challenges and…
2025 Leukemia and Lymphoma Updates: Clarkson’s Disease, Myeloma, and MDS Treatments The field of hematology is witnessing remarkable advancements, offering…
Introduction: A Milestone Achievement for Dr. Peter Zang Peter Zang, MD, a second-year fellow at City of Hope, has reached…
Date: March 19, 2025 On March 19, 2025, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab…
Audio Only: Audio, Video and Slides What’s New in Oncology? – Key Updates from Recent Research Welcome to the latest…
Date: March 11, 2025 Renowned Cancer Researcher Honored in 2025 The American Association for Cancer Research (AACR) and the Pezcoller…
LOS ANGELES AACR IO 2025 At a recent oncology session from AACR Immunotherapy 2025, Melissa G. Lechner, MD, PhD, presented…
March 4, 2025 New Treatment Option for ESCC Patients The U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr)…
Katy Beckermann, MD, PhD – Vanderbilt University The phase 3 TiNivo-2 study (NCT04987203), sponsored by AVEO Pharmaceuticals, Inc., recently…
A Novel Tyrosine Kinase Inhibitor Poised to Transform Advanced Lung Cancer Care Boehringer Ingelheim | Ridgefield, Conn., and Ingelheim, Germany…
Original Authors: Luís F Leite da Silva, Erick F Saldanha, Júnior Samuel Alonso de Menezes, Leonardo Halamy Pereira, João Alexandre…
Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer Institute Cancer immunotherapy has long been dominated…
February 26, 2025 | By Michael Karin, Phd Liver cancer, specifically hepatocellular carcinoma (HCC), is on the rise—and a sneaky…
Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research.…
Los Angeles, February 2025 – The inaugural AACR IO Conference kicked off with an electrifying start, bringing together the world’s…
Could 2025 Oncology Have Saved Steve Jobs from Pancreatic Cancer? A Deep Dive into Past and Future Treatments February 21,…
MRI’s Role in Prostate Cancer Diagnosis – A 3-Year Study Breakthrough Date: February 20, 2025 Prostate cancer, the second most…
FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On…
On February 14, 2025, the U.S. Food and Drug Administration (FDA) delivered a Valentine’s Day gift to patients battling symptomatic…
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At…
Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in MIBC Date: February 14, 2025 Author: Dr. Matthew I. Milowsky, MD,…
Transforming MIBC Treatment: Insights from the NIAGARA Trial Posted on February 16, 2025 The landscape of treating muscle-invasive bladder cancer…
Talazoparib + Enzalutamide Introduction: We are excited to share the latest findings from the TALAPRO-2 Trial, which marks a significant…
Date: February 12, 2025 FDA Approves Adcetris Overview The FDA has approved a new combination therapy for adults with relapsed…
FDA Approves Mirdametinib for NF1-PN: A New Option for Patients Introduction: The FDA has recently approved Mirdametinib (Gomekli) from SpringWorks…
MOASC: Medical Oncology Association of Southern California Welcome to MOASC’s Digital Presence on OncologyTube The Medical Oncology Association of Southern…
Introduction: Recent data from the American Society of Clinical Oncology (ASCO) GI Cancers Symposium 2025, as detailed in their educational…
Date: February 8, 2025 The U.S. Food and Drug Administration (FDA) has recently granted approval for datopotamab deruxtecan (DLNK), a…
Dive into the groundbreaking results of the EMBER-3 Phase 3 trial (NCT04975308) as presented by Dr. Virginia Kaklamani from UT…
The U.S. Food and Drug Administration (FDA) has recently underscored the significance of understanding Dihydropyrimidine Dehydrogenase (DPD) deficiency in patients…
Overview: The results from the Phase 3 CheckMate-8HW trial have just been released, demonstrating significant improvements in outcomes for patients…
Abstract: Circulating tumor DNA (ctDNA) has a short half-life (<2 hours) which may permit real-time monitoring of tumor status. This…
In the rapidly evolving field of cancer treatment, the application of comprehensive genomic profiling (CGP) via liquid biopsy has become…
In the evolving landscape of cancer care In the evolving landscape of cancer care, the use of circulating tumor DNA…
In a recent interview with Dr. Ignacio Garrido-Laguna from the University of Utah Health, we gained fascinating insights into the…
On January 16, 2025, a significant advancement in cancer treatment was announced. The FDA approved a new therapeutic option for…
In an enlightening discussion at the latest medical symposium, Dr. Jonathan Nowak, MD from Brigham and Women’s Hospital, shared critical…
The latest findings from the BREAKWATER study, a phase 3 clinical trial, have shown significant strides in improving treatment outcomes…
By: Elizabeth Catherine Smyth – Cambridge University Hospitals NHS Foundation Trust Background: Oesophagogastric adenocarcinoma (OGA) remains a significant global health…
Background: The treatment landscape for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has been slow to evolve, with limited evidence supporting the…
BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Really Lead to Longevity Leaps? Text: @OncoAlert @oncology @BreastCancerNow @SABCS @ProfMatteoLambertini #SABCS24…
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results Text Version: @DFCI_BreastOnc @Otto_DFCI @OncoAlert @PfizerIbrance @pfizer_news @SABCSSanAntonio @AACR #SABCS24…
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
“So basically, we looked at two factors, the one saying the long term remission of heart positive metastatic breast cancer…
In his analysis, Paolo Tarantino, MD, delves into the transformative potential of CDK4/6 inhibitors in breast cancer therapy. He questions whether these drugs, celebrated for their promise in clinical trials, have truly matched expectations in real-world scenarios, specifically referencing data from the NATALEE and monarchE trials. The discussion is visually represented by a superhero figure donning a CDK4/6 emblem, symbolizing the hope and power these inhibitors bring to the fight against breast cancer. This image captures the essence of current medical debates surrounding the efficacy and application of these treatments in managing breast cancer recurrence and overall patient outcomes.
The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.
The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU®…
EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer Treatment The results of the Phase 3 EMBER-3 trial were unveiled at…
Overview of the CONFORM™ Platform The CONFORM™ platform by EDETEK offers a multifaceted approach to managing clinical data, focusing on…
The GALAXY Study has provided compelling data that highlights the predictive value of circulating tumor DNA (ctDNA) status in colorectal…
The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic…
The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
iTeos Therapeutics and GSK revealed promising results from their phase 2 TIGIT trial at the 2024 European Society for Medical…
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy…
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered…
By: Nathalie M. Johnson, MD – Legacy Health Partners Conference: ASBrS Dr. Nathalie M. Johnson, MD, a breast cancer specialist…
By: Dr. Kevin Hughes, MD, from MUSC Health Conference: ASBrS Introduction Dr. Kevin Hughes, MD, from MUSC Health, sheds light…
Introduction On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or…
On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination…
Introduction ASCO 2024 Head & Neck Cancer developments brought forth several anticipated studies. These studies in the field of head…
By: Dr. Erica Giblin, MD, from Ascension Medical Group Conference: ASBrS Genetic Testing Cancer In recent years, the field of…
By: Barry S. Rosen, MD – Advocate Aurora Health Conference: ASBrS 2024 In the evolving landscape of cancer treatment, ctDNA…
Introduction: In a comprehensive presentation, Dr. Jacob Sands, MD, a medical oncologist, delves into the treatment options for small cell…
Author: Dr. Shubham Pant, MD – MD Anderson Overview: At the ASCO 2024 conference, Dr. Shubham Pant, MD – MD…
Author: Dr. Zandra Klippel, Global Product Head, Multiple Myeloma, Sanofi At the ASCO 2024 conference, Dr. Zandra Klippel the Global…
Author: Dr. Alexis LeVee, City of Hope At the ASCO 2024 conference, Dr. Alexis LeVee from City of Hope presented…
Author: Dr. Regina Barragan-Carillo, City of Hope Overview: At ASCO 2024, Dr. Regina Barragan-Carillo from City of Hope Cancer Center…
Presented by Dr. Hedyeh Ebrahimi, City of Hope Overview: At the ASCO 2024 conference, Dr. Hedyeh Ebrahimi of City of…
… Dr. Sumanta (Monty) Kumar Pal, M.D., FASCO highlights some of the top data and presentations being presented in kidney and…
Dr. Omid Hamid from The Angeles Clinic goes over his favorite presentations coming up at ASCO 2024. Should these be…
Introduction During a comprehensive presentation by Dr. Catherine Coombs at UC Irvine, insights into the unique challenges and opportunities of…
Introduction At a recent conference, Dr. Anjali Advani of the Cleveland Clinic discussed the transformative role of Chimeric Antigen Receptor…
Introduction During the CAR-T & Bispecifics Conference, Dr. Brian Sworder, MD, from UCI Irvine, shared compelling insights on the utility…
Introduction During the recent CAR-T & Bispecifics conference, Dr. Nitin Jain, MD, from MD Anderson Cancer Center in Houston, Texas,…
Introduction The recent findings from the DESTINY-Breast06 Phase III trial signify a potential shift in the treatment landscape for HR-positive,…
Introduction The US Food and Drug Administration (FDA) recently approved nogapendekin alfa inbakicept-pmln (Anktiva), used in conjunction with bacillus Calmette-Guérin…
… Gabriel Mannis, MD Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine provides…
Dr. Charles Link recently discussed the innovative SYNC-T technology (Syncromune® Inc.) during a phase one trial targeting hormone-refractory prostate cancer—a…
Introduction to Emerging Therapies in ALL Management … Dr. Elias Jabbour shared recent developments in the treatment of acute lymphoblastic…
… The field of oncology is continuously evolving, with research focusing on developing more effective and personalized treatment modalities. One…
… Pancreatic cancer, notorious for its lethality and late-stage diagnosis, presents significant challenges in oncological treatment and patient survival. Dr.…
… Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for the…
… Multiple myeloma, an incurable cancer affecting plasma cells in the bone marrow, continues to challenge the medical community. The…
… Introduction Small cell lung cancer (SCLC) is notoriously aggressive and challenging to treat, with current therapies often providing limited…
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in combination with chemotherapy represents a…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
The MOASC represents a prestigious accolade designed to recognize and encourage promising young researchers in the field of oncology. This…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a leading figure in medical…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… Melanoma treatment has significantly evolved due to extensive research and the introduction of novel therapeutic options. Dr. Justin T.…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… Introduction to ADCs in Cancer Therapy The advent of targeted therapies has revolutionized the field of oncology, offering new…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… In the rapidly evolving field of oncology, colorectal cancer (CRC) represents a significant area of research and clinical development.…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… [VIDEO & SLIDES] Alex Chehrazi –Raffle, MD, City of Hope – 2024 MOASC Annual Oncology Summit & Research Symposium…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… [VIDEO with 39 SLIDES] – Dr. Rebecca Shatsky, MD from the 2024 MOASC Annual Oncology Summit & Research Symposium…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
Overview The U.S. Food and Drug Administration (FDA) has granted approval for the use of inotuzumab ozogamicin (Besponsa, Pfizer) in…
On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene…
The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set of challenges for both patients…
Zahra Pakbaz, MD, shed light on a range of critical findings from the American Society of Hematology (ASH) meeting, with…
In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
ASH Groundbreaking Trials and Therapies Transform Multiple Myeloma Treatment The recent American Society of Hematology (ASH) meeting showcased significant advancements…
Assessing the Impact of COVID-19 on Cancer Screening and Diagnosis Rates in the United States: A 2020 Overview The COVID-19…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
March 1, 2024 – In a significant advancement for lung cancer treatment, the Food and Drug Administration (FDA) has approved…
A New Horizon in Gene Editing In the rapidly evolving field of genetic medicine, a groundbreaking development has emerged with…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
On February 15, 2024, the Food and Drug Administration (FDA) approved tepotinib, commercially known as Tepmetko®, for its use in…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews Below) On February 20th, 2024…
What is the new treatment for metastatic melanoma? On February 16, 2024, the medical community witnessed a significant milestone in…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name…
We asked 5 top KOLS at ASCO GI 2024 the same questions on MRD and CTDNA testing. You might be…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… Anup Kasi, MD, Associate Professor and Vice Chair of GI Oncology at the University of Kansas Medical Center, is…
Suneel Kamath, MD: [00:00:00] So this this trial that the tech 24 trial was really looking at a pan G.…
Van K. Morris, MD: [00:00:00] Thanks Allen for for having me and letting me represent our team of investigators who…
Naureen Starling, MD: [00:00:00] Of course. So AZUR-2, as you said, is a global study. Open label, randomized, running in…
Sakti Chakrabarti, MD: [00:00:00] So Dream GI is a national database through which we collect data on localized GI cancer…
Michael Weickert, PhD: [00:00:00] So the first thing I want to explain is Zelenirstat is a first in class therapy…
Thejus Jayakrishnan, MD: [00:00:00] Those of you who have listened to the keynote address today by Dr. Ng from Dana…
Sawyer Bawek, MD: So in colorectal cancer with liver metastasis, studies have shown that immunotherapy has a poor response on…
Anup Kasi, MD: [00:00:00] So this is an investigative initiated trial called the EPIC trial. Where we’re investigating n fotamibidotin,…
Simron Singh, MD: [00:00:00] So radioligand therapy is like in a new emerging treatment for cancer. where we try to…
Howard S. Hochster, MD: [00:00:00] Um, first of all, this is for late line colorectal cancer after the standard chemotherapy…
OncologyTube: [00:00:00] Okay. We’re here at ASCO GI 2024. And, we have the honor of, having Dr. Christopher Lieu, MD…
OncologyTube: [00:00:00] Okay, here we are at ASCO GI 2024. We have Dominik Paul Modest, MD medical doctor from Charite,University…
OncologyTube: [00:00:00] Okay. Okay, we’re here at ASCO GI 2024 and we have Dr. Anthony B. El-Khoueiry, MD a medical…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Dr. Riccardo Lencioni, MD medical doctor, professor…
OncologyTube: [00:00:00] We have Dr. Milind Javle, MD. He is from the Department of Gastrointestinal Medical Oncology at the University…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Jeanne Tie, MD a medical doctor, the medical…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Ghassan K. Abou-Alfa, MD, medical doctor from…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Ethan Ludmir, medical doctor and the assistant…
OncologyTube: Okay, we’re here at ASCO GI 2024. We have Dr. Manish Shah, medical doctor, and the director of gastrointestinal…
  OncologyTube: Okay, we’re here at ASCO GI 2024. We have Dr Stacy Cohen, medical doctor and an associate professor…
Transcript:   Okay, we’re here at ASCO G. I. 2024 and we have Dr. Vivek Sivaya, Medical Doctor, Chief Early…
The full Video OnDemand is now available! This live, virtual, interactive patient education event includes presentations and panel discussions covering…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This…
By. Naval Daver, MD Date: January 12, 2024 Introducing Naval Daver, a faculty member specializing in MD Anderson Cancers in Houston, Texas.…
By: Parrish Phimes, Date: January 12, 2024 Parrish Phimes, a professor of Intology at the University of Oxford and affiliated with…
By: Pramilla Krishnamurthy, MD Date: January 12, 2024 Pramilla Krishnamurthy, md, a consultant hematologist at King’s College Hospital in London, engaged…
By: Priyanka Meta Date: January 11, 2024 Priyanka Meta, a meteorology consultant associated with the University Hospitals of Bristol and…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the integration of circulating tumor DNA…
In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual Disease (MRD). Dr. Mchayleh discusses…
David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s…
Dipti Patel-Donnelly, a medical oncologist at the Virginia Cancer Specialists, leads a study titled “How Can We Manage High-Risk Hematologic…
In the realm of advancements in CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL), Dr. Brian Hill, MD, PhD,…
Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study titled Outcomes of Vdpace for…
John F. Seymour, MBBS, Ph.D., FRACP, a clinical haematologist and the Director of the Haematology Department at Peter MacCallum Cancer…
Asya Nina Varshavsky-Yanovsky, MD, PhD, serves as an Assistant Professor within the Department of Bone Marrow Transplant and Cellular Therapies.…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology, investigates a combination therapy for…
Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology at SA Pathology in Adelaide,…
Rabi Hanna, MD, from the Department of Pediatric Hematology Oncology and BMT at Cleveland Clinic Children’s, conducted a study on…
Evandro Bezerra, MD, hematologist and assistant professor at The Ohio State University Wexner Medical Center, leads research focused on improving…
In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the focus is on investigating the…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina, discussed a multicenter study focusing…
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study titled “Results from an Intergroup…